Premium
ID 1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia
Author(s) -
Damm Frederik,
Wagner Katharina,
Görlich Kerstin,
Morgan Michael,
Thol Felicitas,
Yun Haiyang,
Delwel Ruud,
Valk Peter J. M.,
Löwenberg Bob,
Heuser Michael,
Ganser Arnold,
Krauter Jürgen
Publication year - 2012
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2012.09144.x
Subject(s) - cebpa , npm1 , cancer research , myeloid , biology , survival analysis , medicine , oncology , mutation , gene , genetics , karyotype , chromosome
Summary In acute myeloid leukaemia with normal karyotype ( CN ‐ AML ), gene mutations (e.g. NPM 1 , FLT 3 , CEBPA ) as well as deregulated gene expression affect outcome. High expression of ID 1 was described as a negative prognostic factor. We have shown that CEBPA regulates ID 1 expression. Therefore, we analysed the prognostic impact of ID 1 expression in 269 patients (aged 16–60 years) with CN ‐ AML in the context of other molecular markers, particularly CEBPA mutations. ID 1 high status was an independent negative prognostic factor for overall survival ( OS ) in multivariate analysis when analysed together with age, extramedullary disease, platelets, expression of BAALC and WT 1 , FLT 3 ‐internal tandem duplication, NPM 1 , WT 1 single nucleotide polymorphism rs16754 and IDH 1 . ID 1 expression was higher in CEBPA wildtype patients than in patients with monoallelic CEBPA mutations and these patients showed higher ID 1 expression compared to patients with biallelic CEBPA mutations. Thus, when CEBPA mutations were considered, ID 1 expression lost its prognostic impact. Likewise, the negative impact of ID 1 high status on relapse‐free survival ( RFS ) was lost when CEBPA mutations were included in the analysis. In CEBPA wildtype patients, ID 1 expression had no impact on complete remission‐rate, OS or RFS . In conclusion, CEBPA mutations seem to deregulate ID 1 expression. Therefore, ID 1 expression is not an independent prognostic factor in CN ‐ AML .